Pathogenesis of IBD, and the Role of Biologic Therapies

Slides:

Advertisements

Similar presentations

Methotrexate Indications and Approaches

Advertisements

Thiopurines still have a role in the management of pediatric IBD Athos Bousvaros MD, MPH Associate Director, IBD program Boston Children’s Hospital.

When can we use combination therapy for our pediatric IBD patients? Athos Bousvaros MD, MPH Advances in IBD Dec 2014.

Therapeutic algorithms for Crohn’s disease: Where are we in 2012?

Vedolizumab in Pediatric IBD: We are Ready to Use It

EFFICACY OF EARLY TREATMENT WITH INFLIXIMAB IN PEDIATRIC CROHN’S DISEASE Matthew Sampson.

IBD Cases Stephen B. Hanauer, MD Professor of Medicine Feinberg School of Medicine Medical Director, Digestive Health Center.

William J. Sandborn, M.D., Brian G. Feagan, M.D., Paul Rutgeerts, M.D., Ph.D., Stephen Hanauer, M.D., Jean-Frederic Colombel, M.D., Bruce E. Sands, M.D.,

In the name of God.

The Nurse’s Role in Inflammatory Bowel Disease

MOnoclonal antibodies and potential applications in migraine

Clinical Trials in IBD.

IL-12 and IL-23.

Goals of Therapy for Patients With UC

Optimizing Use of Biological Agents in Ulcerative Colitis

Patient Presentation. Patient Presentation PRIMO Study Incidence of Muscle Adverse Effects.

PCSK9 Loss-of-function Mutations PCSK9-Mediated Degradation of LDL-R.

Current and Emerging Treatments for IBD

Changing the IBD Paradigm

Stepping Up Asthma Control for Effective Management

Biosimilars in RA: A Blessing or a Curse?

Complicated Cases in Ulcerative Colitis

Comparing Treatment Alternatives in Ankylosing Spondylitis

Innovative Insulin Combinations: A New strategy for the Person With T2DM.

Optimizing Patient Outcomes in IBD

Pathways in Managing Ulcerative Colitis

IL-17 Inhibitors in the Management of Psoriatic Disease

An Update on PCSK9 Inhibitors

Clinical Updates in RA: New Developments and Insights From Washington

EHL Technologies in Hemophilia Care

PCSK9 Inhibitors – A Leap in the Evolution of Dyslipidemia Management?

Evolving Treatment Landscape for PsA

Biotherapeutics.

Illustrations in Ulcerative Colitis

Radical New Concepts in Lipid Management

Emerging Frontline Treatments for Patients With Hodgkin Lymphoma

Personalized Therapy in Relapsed or Refractory CLL

Advancing the Treatment of IBD With Biologics

When Is Biologic Therapy Appropriate for HS?

Improving Outcomes in Psoriatic Arthritis

Advances in Multiple Myeloma: Data Highlights and Analysis from the 2015 Hematology/Oncology Conferences.

Key Questions for nAMD Treatment Success

Early Referral for Patients With IBD Failing Conventional Therapies

Monoclonal Antibodies in CVD: What Does the Future Hold?

The Rising Cost of Healthcare and Potential Impact of Biosimilars

Optimizing Outcomes in Crohn Disease

Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer.

Program Goals. Program Goals LDL Established Target for Cardiovascular Risk.

Application of Biologics in IBD:

Essential Updates for PsA: A Complex Disease to Manage

Program Goals Overview Natalizumab Natalizumab: Recent Label Changes.

Figure 1 New therapeutic approaches in IBD therapy based on blockade of T-cell homing and retention Figure 1 | New therapeutic approaches in IBD therapy.

Oral Therapies in MS.

New Lipid-Lowering Therapies

An Update on PCSK9 Inhibitors

Volume 140, Issue 6, Pages e2 (May 2011)

AMD Therapy: Where Are We Now and Where Are We Going?

Tailoring Therapy in the Newly Diagnosed Patient With CLL

Targeting IL-23 for Therapeutic Longevity in Psoriasis

Spotlight on Monoclonal Antibodies in Multiple Myeloma

Crohn’s Disease Biologic Pathway

Difference in the risk of MACEs in patients treated with anti-TNF agents compared with the placebo in RCTs. MACEs, major adverse cardiovascular events;

Comparative Studies of Biologics in Ulcerative Colitis

Disease Activity Cutoffs for ACR-Recommended RA Disease Activity Measure

Overview of irAEs. Management of Immune-Related Adverse Events for Patients Receiving Checkpoint Inhibitor Therapy.

Selective Immunomodulation in MS

Patient Heterogeneity in CD

Psoriatic Arthritis.

You Don't Know JAK in IBD.

Presentation transcript:

Pathogenesis of IBD, and the Role of Biologic Therapies

Learning Objectives

Events Culminating in Intestinal Inflammation

Etiologic Theories in IBD

Genetics of IBD 163 Confirmed Loci

Anti-integrins

Therapeutic Concentrations

Factors that Influence Pharmacokinetics of TNF Antagonists

Anti-TNF Effectiveness in CD and UC

Safety Concerns With Anti-TNF Therapy

Adverse Events With Vedolizumab

All Biologics

Biologics and Immunomodulators in Pivotal Trials

Evidence for Combination Therapy in IBD in Immunosuppressive-naive Patients

TREAT Update Multivariate Logistic Regression Analyses

What Drives Loss of Response to Monoclonal Anti-TNF Antibodies?

Algorithm for Loss of Response to Anti-TNF

Utility of Infliximab and ATI Assays

Summary

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)